Page 687«..1020..686687688689..700710..»

Worm Spitting Powered by Muscle Cells That Perform Two Actions at Once – Howard Hughes Medical Institute

Posted: August 5, 2021 at 1:59 am

Summary

When hungry worms encounter bad-tasting chemicals, they stop eating and spit. To make this switch possible, a muscle in their mouths does two different things simultaneously, splitting up its activity in a way that scientists have never seen before.

Muscle cells can multitask.

In tiny, transparent worms, one type of muscle cell can partition itself so that two areas act independently, a new study reveals. One cell region contracts while a second region undergoes rhythmic contractions and relaxations.

Scientists have generally thought that each muscle cell contractsin a uniformmotion. The collective action of constellations of muscle cells then produces the movements a creature needs to flee a predator, consume a meal, or type an email.

But Howard Hughes Medical Institute Investigator H. Robert Horvitz and colleagues discovered a division of labor within one type of worm muscle cell that allows the animal to protect itself from potentially dangerous chemicals. This multitasking cell lets the worms quickly spit out food they have swallowed, study coauthor Steven Sando, Horvitz, and their colleagues report in the journal eLife on July 2, 2021; the full version of their paper was published on August 3.

This is the first study to show that two compartments within a muscle cell can contract independently, seemingly oblivious to each other, says Horvitz, a molecular geneticist and neurobiologist at the Massachusetts Institute of Technology.

Steves discovery changes the way we think about the control of behavior, because it suggests that individual muscle cells can be partitioned into smaller functional units, adds Horvitz, who shared the 2002 Nobel Prize in Physiology or Medicine for identifying genes that control organ development and programmed cell death.

The roundworm Caenorhabditis elegans gobbles up microbes floating in the water using its tube-like mouth. Muscle cells contract to open a valve at the front of the mouth and to generate suction that pulls in water and microbes. The worms are like little vacuum cleaners for bacteria, Sando says. When the muscle cells relax, the valve closes, causing food to remain trapped in the worms mouth.

Previously, researchers in the lab had observed that when a worm senses noxious chemicals, it stops eating and spits out bubbles and food. Watching through a microscope as these worms spit, Sando noticed that they were holding the front part of their mouths, where the valve is located, open.

Using a laser, he disabled muscle cells lining the mouth and concluded that a single type of cell, called pm3, was responsible for letting the worms spit. By examining the molecular signaling within pm3, Sando showed that the front part of the cell activated independently from the rest.

Sandos results revealed that when a worm spits, the pm3 muscles perform two actions at once. At the front of pm3, a small region contracts to hold the valve open, and it stays contracted while the remaining 90 percent of the cell contracts and relaxes rhythmically to suck in water and then eject it until the worm has cleansed its palate.

In other experiments, Sando traced the key control of this activity to a single neuron. Based on information it receives from taste-sensing cells, this neuron controls whether the worm eats, spits, or performs some variation on these behaviors.

While no one has seen this type of muscle cell multitasking before, scientists already knew of a similar strategy that takes place in the worms gut, and in ours. As part of digestion, wave-like contractions ripple through cells to push food forward. What Sandos team saw was different, however: During spitting, one specific region of pm3 underwent sustained contraction, which didnt propagate to adjacent regions of pm3.

This division of labor may be a strategy that allows the worms to do more with the relatively few cells they possess, says Aravithan Samuel, a biophysicist at Harvard University who was not involved in the study. Like a human, C. elegans is a multicellular organism; however, its body is much simpler, possessing only 959 cells. Even with these limited components, the worm is capable of complex behaviors. Small creatures can do amazing things, he says.

###

Citation

Steven R. Sando et al., An hourglass circuit motif transforms a motor program via subcellularly localized muscle calcium signaling and contraction. eLife. Published online July 2, 2021. doi: 10.7554/eLife.59341

More here:
Worm Spitting Powered by Muscle Cells That Perform Two Actions at Once - Howard Hughes Medical Institute

Posted in Molecular Medicine | Comments Off on Worm Spitting Powered by Muscle Cells That Perform Two Actions at Once – Howard Hughes Medical Institute

Fluoroscopy & C Arms Market Expected to Rise at A High CAGR, Driving Robust Sales and Revenue till 2026 The Manomet Current – The Manomet Current

Posted: August 5, 2021 at 1:59 am

The finest Fluoroscopy & C Arms Marketreport gives better ideas and solutions in terms of product trends, marketing strategy, future products, new geographical markets, future events, sales strategies, customer actions or behaviors. With the precise and high-tech information about industry, businesses can know about the types of consumers, consumers demands and preferences, their perspectives about the product, their buying intentions, their response to particular product, and their varying tastes about the specific product already existing in the market through an influential Fluoroscopy & C Arms Marketreport. Here, market overview is given in terms of drivers, restraints, opportunities and challenges where each of this parameter is studied scrupulously.

The world class Fluoroscopy & C Arms Market report is generated by performing high level market research analysis of key marketplace segments to identify opportunities, challenges, drivers, and market structures for clients. This market survey report brings into focus plentiful of factors such as the general market conditions, trends, inclinations, key players, opportunities, and geographical analysis which all aids to take the business towards the growth and success. In this report, several aspects about the market research and analysis for the industry have been underlined. Fluoroscopy & C Arms Market report has been designed by keeping in mind the customer requirements which assist them in increasing their return on investment (ROI).

Global fluoroscopy and C Arms marketis expected to reach at a CAGR of 4.3% in the forecast period of 2018 to 2025.

This report finally explains in deep the terminologies like the market definition, classifications, applications, and market trends.

The digital fluoroscopy or radiographic imaging systems are used for imaging and produce visible electronic images of patients for treatment.

Get Sample copy of this Report @https://databridgemarketresearch.com/request-a-sample/?dbmr=global-fluoroscopy-c-arms-market

Major Players:Global Fluoroscopy & C Arms Market

Some of the prominent participants operating in this market are GE Healthcare, Koninklijke Philips N.V., Siemens AG, Canon Medical Systems Corporation, Shimadzu Corporation, Carestream Health, EcoRay, Eurocolumbus s.r.l., GEMSS Co., Ltd., Hitachi, Ltd., Hologic Inc., INTERMEDICAL S.r.l., ITALYRAY, PAUSCH Medical GmbH, Varex Imaging Corporation, Whale Imaging, and Ziehm Imaging GmbH among others.

Study Highlights

Request For TOC@https://databridgemarketresearch.com/toc/?dbmr=global-fluoroscopy-c-arms-market

Segmentation:

By Fluoroscopy Type (Conventional Fluoroscopy Systems, Remote-Controlled Fluoroscopy Systems), C Arm Type (Fixed C-Arms, Mobile C-Arms), C Arm Technology (Flat Panel, Image Intensifiers), Application (Diagnostic Applications, Surgical Application, Discography), End User (Hospitals, Diagnostic Centers, Specialty Clinics), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Industry Trends and Forecast to 2026

GE Healthcare:

GE Healthcare founded in 1918, headquarters in New York, U.S., and focuses towards the manufacturing and developer of medical imaging, digital solutions, patient monitoring and diagnostics, drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions.

The company has its presence in U.S, Europe, Asia, Americas, Middle East and Africa.

Koninklijke Philips N.V.:

Koninklijke Philips N.V., founded in 1891 and based in Amsterdam, Netherlands. The company focuses on improving peoples health and enabling better outcomes across the health continuum from healthy living and prevention to diagnosis, treatment and home care.

The company has its presence in Netherland, United states, China, Germany, Japan, France, India and Others.

Siemens AG:

Siemens AG, founded in 1896 and based in Munich, Germany. The company provides manufacturing, distributing and services of medical devices and pharma Services. Company is engaged in providing precision medicines, transforming care delivery, innovative technology in area of diagnostics, molecular medicine and many others. The company has its presence in Europe, C.I.S., Africa, Middle East, Americas , Asia, Australia.

Market Developments:

Inquiry Before Buying AThttps://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-fluoroscopy-c-arms-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email:sopan.gedam@databridgemarketresearch.com

See the original post here:
Fluoroscopy & C Arms Market Expected to Rise at A High CAGR, Driving Robust Sales and Revenue till 2026 The Manomet Current - The Manomet Current

Posted in Molecular Medicine | Comments Off on Fluoroscopy & C Arms Market Expected to Rise at A High CAGR, Driving Robust Sales and Revenue till 2026 The Manomet Current – The Manomet Current

Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU – GlobeNewswire

Posted: August 5, 2021 at 1:59 am

August 3, 2021

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that New York Langone Healths Department of Pathology will leverage Philips Genomics Workspace (formerly part of IntelliSpace Precision Medicine Platform) to integrate into their EMR (electronic medical record) environment. This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis.

Genetic test for all cancers designed by NYU Langones molecular pathologistsCleared by the FDA (U.S. Food and Drug Administration) earlier this month under its 510(k) designation for clinical lab use, the NYU Langone Genome PACT (Profiling of Actionable Cancer Targets) test detects changes in the DNA code of 607 genes linked by past studies to the development of multiple types of cancer. The number of genes cancer types assayed is the largest among academic genomic sequencing tests of its kind.

PACT uses next-generation sequencing (NGS) technology, which can read the sequence of the molecular letters making up DNA code within hundreds of genes simultaneously, and covers the most genes of any FDA-cleared NGS test to-date. The technology matches the genetics of each patients tumor cells with a growing number of approved therapies targeted to address specific sets of cancer-causing DNA changes.

The work currently underway at NYU Langone is ground-breaking in the area of genomic sequencing and we are honored to be teaming on the development efforts, including building an interface between the new test and NYU Langone Healths electronic medical records system, said Louis Culot, General Manager of Oncology Informatics at Philips. Philips Genomics Workspace, hosted on cloud-based Philips HealthSuite, will help facilitate the integration into the EMR so tests can be seamlessly ordered, reviewed, and shared by a patients care team.

PACT reaffirms the goal behind its design, which was to provide our patients with the best understanding of the genetic changes driving their cancers, said PACT designer Matija Snuderl, MD, director of Molecular Pathology and Diagnostics in the Department of Pathology at NYU Langone Health. Knowing the genetics of their tumor can help to determine which therapies will work for a given patient and their eligibility for specific clinical trials. Beyond the genetic changes that are important to the field now, we also wanted PACT to detect the changes anticipated to be important in diagnosis and treatment of cancer over the next five to ten years.

Philips end-to-end oncology solutions driving a clear path to precision cancer careAccording to the National Cancer Institute, patients today usually receive the same treatment as others who have same type and stage of cancer, despite growing evidence that they may respond differently [1]. Philips approach to precision medicine is to arm care teams with expert clinical guidance and a holistic view of the patients genotypic (the set of genes in the DNA) and phenotypic (observable characteristics influenced by environmental and lifestyle factors) information in order to make decisions efficiently, collaboratively and accurately. Recognizing the growing need for technological advancement in oncology care from early detection to diagnosis to treatment to survivorship Philips connects areas such as pathology, genomics, molecular/multi-disciplinary tumor boards, therapy decision making, molecular and imaging phenotyping, so clinicians can have easy access to the insights they need to provide high-quality personalized care.

With Philips Genomics Workspace, oncologists can map a patients uniquecharacteristics to a therapy that is best suited for them and provide evidence on why that therapy is preferable. Philips genomics solution combines individual institution genomic knowledge bases and general industry knowledge bases, to help molecular pathologists interpret genomic data and to provide clinicians with ways to enable improved patient care. Visit Philips Precision Medicine to learn more.

[1] https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment.

For further information, please contact:

Kathy OReillyPhilips Global Press OfficeTel.: + 1 978-221-8919E-mail: kathy.oreilly@philips.comTwitter: @kathyoreilly

Greg WilliamsResearch Communications DirectorNYU Grossman School of MedicineTel: +1 212-404-3500E-mail: Gregory.williams@nyulangone.org

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.

Visit link:
Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU - GlobeNewswire

Posted in Molecular Medicine | Comments Off on Philips Genomics Workspace enables integration of the largest-scale FDA-cleared cancer genetic test at NYU – GlobeNewswire

Study: Physical Exercise Improves Health of Brain and Other Organs through Epigenetic Changes | Medicine, Physiology – Sci-News.com

Posted: August 5, 2021 at 1:59 am

Some sections of our DNA are genes, which are instructions for building proteins, while other sections called enhancers regulate which genes are switched on or off, when, and in which tissue. New research from the University of Copenhagen and the Karolinska Institutet provides evidence of a functional link between epigenetic rewiring of enhancers to control their activity after exercise training and the modulation of disease risk in humans.

Exercise training rewires the enhancers in regions of our DNA that are known to be associated with the risk to develop disease. Image credit: Sasin Tipchai.

Regular physical activity decreases the risk of multiple common disorders such as cardiovascular disease, type 2 diabetes, cancer, and neurological conditions, along with the overall risk of mortality, said Professor Romain Barrs from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen and colleagues.

The beneficial effects of exercise training on human health are partially driven by adaptations of the skeletal muscle tissue.

Exercise-induced adaptations include coordinated changes in the expression of genes controlling substrate usage and metabolic efficiency in skeletal muscle.

In addition to the adaptations that occur within skeletal muscle cells, exercise exerts systemic effects on whole-body homeostasis by triggering the release of soluble factors from the muscle that signal to distal tissues, such as brain, liver, and adipose tissue.

The mechanisms by which training-induced adaptations of skeletal muscle orchestrate positive effects at the whole-body level are poorly understood.

We hypothesized that endurance exercise training remodels the activity of gene enhancers in skeletal muscle and that this remodeling contributes to the beneficial effects of exercise on human health.

For the study, the researchers recruited eight healthy Caucasian men (mean age 23 years) and put them through a six-week endurance exercise program.

They collected a biopsy of their thigh muscle before and after the exercise intervention and examined if changes in the epigenetic signature of their DNA occurred after training.

They discovered that after completing the endurance training program, the structure of many enhancers in the skeletal muscle of the young men had been altered.

By connecting the enhancers to genetic databases, the scientists found that many of the regulated enhancers have already been identified as hotspots of genetic variation between individuals.

Our findings provide a mechanism for the known beneficial effects of exercise, Professor Barrs said.

By connecting each enhancer with a gene, we further provide a list of direct targets that could mediate this effect.

The authors speculate that the beneficial effects of exercise on organs distant from muscle, like the brain, may largely be mediated by regulating the secretion of muscle factors.

In particular, they found that exercise remodels enhancer activity in skeletal muscle that are linked to cognitive abilities, which opens for the identification of exercise training-induced secreted muscle factors targeting the brain.

Our data provides evidence of a functional link between epigenetic rewiring of enhancers to control their activity after exercise training and the modulation of disease risk in humans, said Dr. Kristine Williams, also from the Novo Nordisk Foundation Center for Basic Metabolic Research at the University of Copenhagen.

The findings are published in the journal Molecular Metabolism.

_____

Kristine Williams et al. Epigenetic rewiring of skeletal muscle enhancers after exercise training supports a role in the whole-body function and human health. Molecular Metabolism, published online July 10, 2021; doi: 10.1016/j.molmet.2021.101290

More here:
Study: Physical Exercise Improves Health of Brain and Other Organs through Epigenetic Changes | Medicine, Physiology - Sci-News.com

Posted in Molecular Medicine | Comments Off on Study: Physical Exercise Improves Health of Brain and Other Organs through Epigenetic Changes | Medicine, Physiology – Sci-News.com

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor – GlobeNewswire

Posted: August 5, 2021 at 1:59 am

SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing. The financing was led by Fidelity Management & Research Company, LLC., with participation from other new investors including, LSP, Qatar Investment Authority (QIA), Casdin Capital, Sixty Degree Capital, and CaaS Capital, along with existing investors RA Capital Management, Versant Ventures and founding investor Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).

Over the past year we have made substantial progress toward our goal of building a leading TCR-T company focused on delivering clinically meaningful benefits for patients with solid tumors, stated Thomas M. Soloway, Chief Executive Officer of T-knife. We are excited to have the support of this group of dedicated life sciences investors to help us fulfill our mission, and we welcome Dr. Karin Kleinhans of LSP to our board of directors.

T-knife has an elegant and differentiated approach to identifying potent, cancer-specific TCRs with naturally optimized affinity and specificity profiles, creating a next-generation platform for this promising therapeutic field, said Alex Mayweg, Chairman of T-knife and Managing Director at Versant Ventures. We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates.

T-knife is leveraging its proprietary HuTCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. T-knifes lead program, TK-8001, is a novel TCR-T product candidate targeting MAGE-A1 positive cancers. T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product candidates in 2022.

"The field of TCR-T holds significant promise to change the treatment paradigm for many cancer patients, said Karin Kleinhans, PhD, Partner at LSP who joined T-Knifes board in connection with the Series B financing. We are highly encouraged by the progress being made at T-knife to advance its important next-generation therapies.

Olivier Litzka, Partner at Andera Partners, commented, As a founding investor, it is gratifying to witness the continued success at T-knife. The completion of the Series B financing is an important milestone that will enable us to execute on our vision of building a leading transatlantic immuno-oncology company.

About the HuTCR platformT cells play a key role in the immune response by directly recognizing and eliminating infected, foreign or altered cells, such as cancer cells. To do this, they use their T-cell receptors (TCRs) to scan the surface of other cells for foreign antigens presented on Human Leukocyte Antigen (HLA) complexes. Cancer cells can be recognized by mutated or viral antigens expressed only in the tumor, or self-antigens normally expressed during embryonic development and in non-somatic adult tissues. Genetic engineering of T cells with TCRs recognizing antigens aberrantly or over-expressed in cancers can redirect these T cells to the tumor, potentially offering curative responses to cancer patients.

The ability to identify potent cancer-specific TCRs has been limiting for the field of TCR-T. In the case of self-antigens, T cells bearing those TCRs are eliminated during T cell development to avoid recognition and attack of healthy tissues. For non-self tumor antigens, such as those derived from viral sequences or mutations, the very low T cell frequency in the blood has limited TCR discovery efforts.

To overcome these challenges, T-knife has developed transgenic mice (HuTCR mice) carrying the human TCR gene loci and expressing multiple human HLAs. Immunizing HuTCR mice with human tumor antigens, for which mice are not tolerant, allows for the identification of both CD4+ and CD8+ T cells with TCRs that have optimized affinity / specificity profiles capable of mediating significant anti-tumor activity. The TCRs from HuTCR mice are of higher affinity for tumor self-antigens than TCRs isolated from human donors and are naturally optimized to maintain a high specificity profile, making HuTCR mice a powerful high-throughput platform for rapidly generating TCRs with best-in-class potential.

About T-knife TherapeuticsT-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully human TCRs, naturally selected in vivo for optimal affinity and specificity.

T-knife is developing a pipeline of potential first/best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charit University Hospital in Berlin. For additional information, please visit the companys website at http://www.t-knife.com.

Contact T-knife Therapeutics, Inc.Camille Landis Chief Business Officer / Chief Financial Officerinfo@t-knife.com

Sylvia WheelerWheelhouse Communicationsswheeler@wheelhouselsa.com

Dr. Ludger Wess / Ines-Regina Buthakampioninfo@akampion.com

Read the original here:
T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor - GlobeNewswire

Posted in Molecular Medicine | Comments Off on T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor – GlobeNewswire

Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant…

Posted: August 5, 2021 at 1:59 am

DetailsCategory: More NewsPublished on Wednesday, 04 August 2021 13:50Hits: 298

HOUSTON, TX, US AI August 04, 2021 I Excel Diagnostics and Nuclear Oncology Center (EDNOC), a premier Diagnostic Imaging and Radioligand Therapy center in Houston, Texas announces approval of its physicians sponsored Investigational New Drug (IND) application for providing Targeted Alpha Therapy (TAT) with 225Ac-PSMA I&T for metastatic Castration-Resistant Prostate Cancer (mCRPC). We are glad to be able to make this game-changing drug available to our patients suffering from mCRPC. Excel Diagnostics and Nuclear Oncology Center has been a pioneer in bringing new targeted Radioligand Therapies such as Lu-177 DOTATATE, and Lu-177 PSMA to serve our patients in the United States. The addition of 225Ac-PSMA I&T is in continuation of our mission to address unmet needs in the field of Nuclear Oncology said Dr. Ebrahim Delpassand, Chairman and Medical Director of EDNOC and Co-Principal Investigator of the trial. PSMA is an established prostate cancer target. Highly encouraging results have been reported by using Targeted Alpha Therapy (TAT) Radiopharmaceuticals in conditions such as neuroendocrine, prostate, or hematological malignancies. These breakthroughs have brought a significant amount of hope to our patients suffering from different types of advanced cancers. said Dr. Rodolfo Nuez, Director of Nuclear Medicine Department at EDNOC and Co-Principal Investigator of the trial. We are pleased to be able to facilitate the availability of 225Ac-PSMA I&T by manufacturing this drug at RadioMedix. We firmly believe that the menu of targeted Radioligand Therapies will only increase in the future. RadioMedix with its wide range of capabilities, from drug discovery to scale-up commercial manufacturing, is ready to meet this challenge said Dr. David Ranganathan, Director of CMC and Regulatory affairs at RadioMedix.

About Excel Diagnostics and Nuclear Oncology Center (EDNOC)

EDNOC is a premier outpatient facility offering a full spectrum of diagnostic imaging, nuclear medicine and Radioligand therapies. In addition to our comprehensive and state-of-the-art imaging services, we have assembled a staff of highly skilled technical and medical professionals to meet and exceed the demanding standards of the industry. EDNOC is fully capable of conducting sponsored clinical research trials in the field of diagnostic and therapeutic nuclear medicine. All our research staff is GCP Trained and CITI certified consisting of highly trained, board-certified investigators, study coordinators, patient recruiters, and support staff. At Excel, you will find areas designed to safely handle and administer radiopharmaceuticals, patient care areas, and physician interpretation resources. The Excel Clinical Research Department (ECRD) is a dedicated department to assist investigators in their clinical trials. Our team is fully trained regarding rules and regulations of conducting human research, FDA requirements, and IRB compliance. We offer our expertise in conducting clinical research to a variety of academic institutions and pharmaceutical companies. ECRD works closely with CROs & IRBs, to support sponsored clinical trials in the field of oncology radiopharmaceuticals. In April of 2020, Excel passed FDA inspection of one of its investigational drugs with no deficiencies or citations. For more information, please visit us at: http://www.exceldiagnostics.com

About RadioMedix

RadioMedix, Inc. is a clinical-stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is developing radiopharmaceuticals for PET imaging and therapy (alpha and beta-labeled). RadioMedix has also established contract service facilities for academic and industrial partners including drug discovery and probe development core facility, a small animal molecular imaging facility for pre-clinical evaluation of radiopharmaceuticals, and cGMP and analytical suites for late-stage human clinical trials, and post-approval commercial manufacturing. To learn more, visit http://www.radiomedix.comand LinkedIn. For more information about this press release, please contact:This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

SOURCE: RadioMedix

Here is the original post:
Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant...

Posted in Molecular Medicine | Comments Off on Excel Diagnostics and Nuclear Oncology Center Announces FDA Authorization of IND for 225Ac-PSMA I&T Targeted Alpha Therapy for Castration Resistant…

Supernus Announces Second Quarter 2021 Financial Results

Posted: August 5, 2021 at 1:55 am

ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the second quarter of 2021, and associated Company developments.

Go here to see the original:
Supernus Announces Second Quarter 2021 Financial Results

Posted in Global News Feed | Comments Off on Supernus Announces Second Quarter 2021 Financial Results

Aleafia Health to Announce 2021 Second Quarter Results

Posted: August 5, 2021 at 1:55 am

TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) will announce its 2021 second quarter results on August 12, 2021 prior to market open. The Company will also host its earnings conference call the same day at 9:30 a.m. ET. The call will be hosted by CEO Geoffrey Benic and CFO Matt Sale.

Read the original post:
Aleafia Health to Announce 2021 Second Quarter Results

Posted in Global News Feed | Comments Off on Aleafia Health to Announce 2021 Second Quarter Results

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

Posted: August 5, 2021 at 1:55 am

Diagnostics industry expert to lead commercialization of marketed products and drive global commercial expansion Diagnostics industry expert to lead commercialization of marketed products and drive global commercial expansion

Read the rest here:
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

Posted in Global News Feed | Comments Off on Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Posted: August 5, 2021 at 1:55 am

WESTMINSTER, Colo., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2021 financial results and provided a corporate update.

Go here to read the rest:
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Posted in Global News Feed | Comments Off on ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Page 687«..1020..686687688689..700710..»